

A. Mina Tran

12966 Euclid Street, Suite 310
Garden Grove, California 92840
(714) 427-0222 Fax. (714) 427-0225
www.tranlawgroupus

August 22, 2016

OTC Markets Group
304 Hudson Street Second Floor
New York, New York 10013

Re: Adequate Current Information of Supurva Healthcare Group, Inc. (Symbol: SPRY),
Opinion of Counsel regarding Adequate Current Information and Continuing Disclosure
Requirements for the year ending December 31, 2015 and the seven Months Ended July
31, 2016.

Dear Sir or Madam:

This firm has acted as legal counsel for Supurva Healthcare Group, Inc. ("SPRV") or "the Company" and has been retained for the purpose of preparing this Opinion of Counsel, applying the applicable laws of the United States, regarding its corporate operations and level of disclosure of corporate information. I am not currently or ever have been under any State or Federal investigation. I am a resident of the United States and have been retained by the Issuer for the purpose of rendering this letter and related matters.

We have examined such corporate records and other documents and such questions of law as we have deemed necessary or appropriate for purposes of rendering this opinion. As to matters of fact, we have made such inquiries of the Issuer's officers as we deemed necessary to render this opinion, and we believe that such sources were reliable.

You are entitled to rely on this letter in determining whether Supurva Healthcare Group, Inc. (the "Issuer" or "Company" has made adequate current information publicly available within the meaning of Rule 144(c) (2) under the Securities Act of 1933.

This letter relates to the laws of the United States, specifically Federal securities law. I have been a member in good standing of the bar of the State of California and I have not been prohibited from practice thereunder.

The Issuer is not a reporting company and, therefore, does not file annual or other reports with the SEC. I have reviewed publicly available information relating to the Issuer including: the Issuer's profile posted on the OTC Markets Group website; the information from January 1, 2014 through July 15, 2016 posted as Press Releases on the OTC Disclosure & News Service; and the Company's Annual Report for the period ending December 31, 2014, filed with the OTC Markets Group on May 12, 2015 (the "Information"). Along with the company's most recent filing covering the "Financial report as of December 31, 2015, Quarterly Report for the Quarter Ending June 30, 2016, . I have also reviewed the Articles and Corporate Bylaws of the Company.

It is my opinion that the Information (1) constitutes adequate current public information concerning the Issuer's securities and is available within the meaning of Rule 144(c)(2) under the OTC Markets Group Securities Act of 1933; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iii) complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com; and (iv) has been posted through the OTC Disclosure and News Service.

The party responsible for the preparation of the unaudited financial statements of Supurva Healthcare Croup, Inc. is Jim Farooquee who has served as the President and Director for the company for three months and owned and operated his own private and public company for 40 years.


The Issuer's transfer agent is Madison Stock Transfer, which is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information Statement was to examine a shareholder list issued by the transfer agent, as of July 31, 2016, and received confirmation as to the number of shares outstanding. As of July 31, 2016, the total outstanding shares of common stock of the Issuer were 5,487,085,697.

I have personally spoken with the President Jim Farooquee and sole director of the Issuer; I have reviewed the Information, as amended, published by the Issuer through the OTC Disclosure and News Service; and I have discussed the Information with the chief executive officer and sole director of the directors of the Issuer.

To the best of my knowledge, after inquiry of the chief executive officer and sole director of the Issuer, neither, counsel nor any officer, director or shareholder of the securities of the Issuer is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

No person other than the OTC Markets Group is entitled to rely on this letter. However, I hereby grant the OTC Markets Group full and complete permission and rights to publish the letter through the OTC Disclosure and News Service for viewing by the public and regulators.

Very Truly Yours,



A. Mina Tran